Annovis Bio announced last patient last visit in the phase II/III study of its lead candidate buntanetap in patients with mild to moderate Alzheimer’s disease, AD. “The completion of the Alzheimer’s study marks a significant step in our efforts to bring new therapies to patients,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis. “The study progressed as intended with minimal dropout rate.”A total of 327 patients have successfully concluded the phase II/III trial out of the initial 353 enrolled.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ANVS:
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Largest borrow rate increases among liquid names
- Annovis Bio falls -9.6%
- Annovis Bio files $250M mixed securities shelf
- Annovis Bio announces filing of new patent application for mental illnesses
